DECK 7 Optimizes Its Strategic Marketing for 2020 Using a Revised ABM Strategy

DECK 7 | February 04, 2020

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. The DECK 7 team has created a simple, yet effective framework for executing ABM at scale; it consists of a comprehensive and strategic approach in order to identify, target, engage, activate, and measure success in real-time.

Spotlight

Raman spectroscopy has taken large strides in recent years as more Raman vendors have developed handheld Raman units capable of carrying out raw material identification or verification. Raman spectroscopy is used as a fingerprinting tool to capture the unique Raman spectrum of each raw material. There are many benefits of adopting this new Process Analytical Technology (PAT) tool to the biopharmaceutical industry. Critical technical considerations and unique challenges that must be overcome to implement Raman spectroscopy in the biopharmaceutical industry are discussed.

Spotlight

Raman spectroscopy has taken large strides in recent years as more Raman vendors have developed handheld Raman units capable of carrying out raw material identification or verification. Raman spectroscopy is used as a fingerprinting tool to capture the unique Raman spectrum of each raw material. There are many benefits of adopting this new Process Analytical Technology (PAT) tool to the biopharmaceutical industry. Critical technical considerations and unique challenges that must be overcome to implement Raman spectroscopy in the biopharmaceutical industry are discussed.

Related News

PHARMACY MARKET

BC Platforms Adds Japans Mitsubishi Space Software to its Global Data Network

BC Platforms | February 21, 2022

BC Platforms (BCP), a global leader in healthcare data management and analytics, announced a new data partnership with Japan's Mitsubishi Space Software Co. Ltd. (Mitsubishi), one of the country's oldest bioinformatics companies. The collaboration, which provides secure access to Mitsubishi's cancer specific cohort of 8,000 patients, will accelerate the provision of cancer genetic data analysis services to medical institutions for cancer research. As part of the collaboration, Mitsubishi joins BCP's BCRQUEST network, which is revolutionizing drug development & personalizing care. This global, federated data partner network enables analytics and deeper insights. BCP has built this network, which reaches over 22 million patient lives in the catchment area, and data partners across Europe, North America, and Asia-Pacific to enable the realization of the full potential of real-world data. "At BCP, our mission is to accelerate the translation of research into global clinical practice through the faster generation of translatable, actionable, research insights. We encourage health systems to invest in consenting and data infrastructure as it provides strong foundations underpinning personalized medicine and ultimately improve outcomes for patients. Through our partnership with Mitsubishi, a long-standing leader in the field of bioinformatics, we expect patient lives will be directly, positively, impacted. This collaboration also adds significant data from millions of Asian patients to fuel research with connections to 30 hospitals in Japan. Such achievements are part of our continued efforts to scale our vision to build the world's leading analytics platform for healthcare and the life sciences industry." Nino da Silva, Deputy Managing Director, BCP Mitsubishi Space Software Co., Ltd., commented, "At Mitsubishi, we have long been supporting patients by utilizing and researching genomic research and providing cancer genetic data analysis services to medical institutions for cancer research. We are looking forward to working with BC Partners, and its BCRQUEST network, to enhance Japan's provision of clinical and genomic datasets to benefit research, patient care and personalized medicine." This latest data partnership builds on recent successes of delivering industry-leading interpretation services on genomics related insights, including pharmacogenomics in clinical practice in Asia and around the world. In October 2021, BCP announced its partnership with Bumrungrad International Hospital (BIH), in Bangkok, Thailand, one of the largest private hospitals in Southeast Asia and a world leader in healthcare delivery and pioneering clinical research. BCP is supporting BIH on its transition from single-gene tests to multi-gene panels for clinical pharmacogenetics, providing data interpretation support on single nucleotide variations. About BC Platforms BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine, accelerating the translation of insights into clinical practice. Our technology drives the infinite loop between personalized care and research discoveries, leveraging latest science, deep technical expertise, strategic partnerships, and harmonized, diverse data collections. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. Additionally, BC Platforms has developed a Global Data Partner Network BCRQUEST.com, which allows us to access real-world data equivalent to approximately 22 million patient lives, including longitudinal clinical data in addition to 500k patients' genetic data, across 14 countries in Europe, North and South America, Asia and Africa, providing rich data for pharmaceutical and medical research and development. About Mitsubishi Space Software Mitsubishi Space Software was established in 1962 as a system engineering company. Our cooperate mission is "We support future society with high-quality and highly reliable solutions based on advanced science and technology which are cultivated by space system development."

Read More

RESEARCH

Pfizer and Biontech Nab Covid-19 Vaccine Authorization from U.K. For First-ever Marketed mRNA shot

Pfizer | December 03, 2020

The two organizations' BNT162b2 has become the primary COVID-19 immunization permitted in the Western world as medication controllers in the U.K. given out a crisis use approval on Wednesday, in front of choices by the U.S. also, Europe, which are normal soon. For the more extensive immunization world, the Medicines and Healthcare items Regulatory Agency's choice methods the world currently has the principal mRNA shot approved for far reaching use, opening up a fresh out of the box new part for antibody advancement. The principal portions will be conveyed to the U.K. quickly, the organizations said. A representative at the U.K's. Department of Health and Social Care said the antibody will be made accessible the nation over from one week from now. The U.K. has requested 40 million portions of the antibody—enough to immunize 20 million individuals—through an arrangement endorsed in July and extended in October. "As we envision further approvals and endorsements, we are centered around moving with a similar degree of criticalness to securely flexibly an excellent immunization around the globe. With a great many individuals turning out to be tainted, each day matters in the aggregate competition to end this staggering pandemic," Pfizer CEO Albert Bourla, Ph.D., said in an explanation, calling the U.K. gesture a "noteworthy second." Pfizer has appointed COVID-19 antibody assembling to three destinations in the U.S. also, one in Belgium. BioNTech has offices in Mainz and Idar-Oberstein in Germany, which have been delivering dosages for clinical preliminaries. The German biotech as of late purchased a Novartis plant in Marburg, Germany, to quicken business assembling of the COVID-19 immunization. In general, the two organizations have said they can create up to 50 million dosages in 2020 and up to 1.3 billion portions in 2021.

Read More

Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV

Moleculin Biotech, Inc | October 07, 2020

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV-2, antiviral activity has now been documented for HIV, Zika and Dengue Fever.

Read More